Life-science briefing: Thursday, April 3, 2008

Life-science briefing: Thursday, April 3, 2008

TODAY’S HEADLINES:

Mirna Thera spins out of Asuragen with $3M (release)
Stroke-therapy startup CoAxia raises $12M (release)
Stealthy device maker Synvascular gets $6.5M (peHUB)
AndroScience seeks $3.5M for anti-testosterone drugs (VentureWire)
Austria’s ProtAffin takes in €1.1M grant (release)
Singapore’s Moleac receives $3.5M for Chinese medicine (release)
Alethia Bio gets C$2.4M for antibody… Continue Reading

Life-science briefing: Friday, March 14, 2008

Life-science briefing: Friday, March 14, 2008

TODAY’S HEADLINES

Cantimer takes in $2M for dehydration diagnostics (VentureWire)
Recodagen launches, takes aim at cancer (release)
Juniper Diagnostics spins out of ChemSensing (VentureWire)

Cantimer takes in $2M for dehydration diagnostics –The mystery of Menlo Park, Calif.-based Cantimer has resolved a bit. We wrote about this stealthy company back… Continue Reading

Life-science briefing: Tuesday, March 11, 2008

Life-science briefing: Tuesday, March 11, 2008

TODAY’S HEADLINES:

Affinergy gets $3M in grants for biological “linkers” (release)
Specialty pharma EUSA raises $50M, spends $23M for public biotech Cytogen (release)
Calderome takes in $12M for cancer diagnostics (peHUB)
Pulse Health raises $2M for handheld free-radical device (release)

LifeMasters takes in $15M for wellness, disease-management programs (release)
Dubai Techno… Continue Reading

Precision Thera merger with “blank check” firm Oracle Healthcare collapses

Precision Thera merger with “blank check” firm Oracle Healthcare collapses

(UPDATED: See below.)

Another one bites the dust.

The saga of Precision Therapeutics, a Pittsburgh biotech developing what struck me last August as a particularly crude type of cancer-chemotherapy diagnostic, continues apace. In a tersely worded press release, the special-purpose acquisition company, or SPAC, Oracle Healthcare Acquisition said… Continue Reading

Life sciences briefing: Wednesday, March 5, 2008

Life sciences briefing: Wednesday, March 5, 2008

TODAY’S HEADLINES:

Precision Thera merger with “blank check” Oracle Healthcare collapses (release)
Sleep Solutions takes in $21M for sleep-apnea diagnostics (release)

Trevena takes in $24M for drugs targeting G-proteins (release)
“Specialty biotech” PanGenetics gets €23M for antibody drugs (release)
Cancer-drug maker Unibioscreen pulls in €5M (release)
Danish contract manufacturer CMC Biologics… Continue Reading

Life sciences briefing: Thursday, Feb. 28, 2008

Life sciences briefing: Thursday, Feb. 28, 2008

TODAY’S HEADLINES:

RNAi developer PhaseRx gets $4M of a pledged $19M (Seattle Times)
TyRx Pharma, drug-device combo maker, raises $25M (release)
Agennix aims at $40M for cancer drugs (VentureWire)
Starr Life Sciences goes after $1.6M for small-animal vital-signs scanner (VW)
CardioNet sets IPO terms, aims to raise $96M (IPOhome)

RNAi developer… Continue Reading

Life sciences briefing: Wednesday, Feb. 27, 2008

Life sciences briefing: Wednesday, Feb. 27, 2008

TODAY’S HEADLINES:

InSound Medical raises $11M for “invisible” hearing aids (VBLS exclusive)
Corventis takes in $20M for heart-failure therapy (VBLS exclusive)
Molecular diagnostics user AssureRx raises $1M (Cincinnati Enquirer)
Arresto Biosciences, cancer-drug developer, raises funds (VentureWire)
San Diego’s Obalon raises $4.7M for drug discovery (peHUB)

InSound Medical raises $11M for “invisible”… Continue Reading

Life sciences briefing: Monday, Feb. 4, 2008

Life sciences briefing: Monday, Feb. 4, 2008

TODAY’S HEADLINES:

PEAK Surgical takes in $21M for electrosurgical tools (release)
CellGate acquired by Australian cancer biotech ProGen for $2.5M (release)
Traversa raises $2M for RNAi-delivery technologies (release)
RemitDATA, Web-based healthcare-service co., takes in $5.5M (bizjournals.com)
Spinal-implant maker Archus Orthopedics gets $10M venture loan (release)
Promedior pulls down another $5.5M for… Continue Reading

Life sciences briefing: Friday, Jan. 25, 2008

Life sciences briefing: Friday, Jan. 25, 2008

TODAY’S HEADLINES:

Health-info site HealthCentral Network pulls in $50M (paidContent)
BrightHeart Vet corrals $29M to acquire animal hospitals (release)
AviaraDx raises $8M for cancer diagnostics (peHUB)
Valor Medical aims for $15M for brain-aneurysm treatment (VentureWire)
IPC, inpatient-care provider, raises as much as $56M in IPO (IPO Home)
Phenomix, diabetes and hepatitis… Continue Reading

Life sciences briefing: Thursday, Jan. 24, 2008

Life sciences briefing: Thursday, Jan. 24, 2008

TODAY’S HEADLINES:

Satoris gets $5M for Alzheimer’s test (VentureWire)
Endotis Pharma pulls in €25M for clot-busting and cancer drugs (release)
Germany’s Direvo Biotech strikes drug-development pact with MedImmune (release)
OrthoAccel gets $1.3M for device to speed orthodonture (VW)
Medical-management software co. Accuro Healthcare files for $144M IPO (Edgar)
Psilos Group raises… Continue Reading

Life sciences briefing: Monday, Jan. 14, 2008

Life sciences briefing: Monday, Jan. 14, 2008

TODAY’S HEADLINES:

Autonomic Technologies raises $3M for neurostimulators (PE Hub)
Canopy Financial raises $15M for outsourced healthcare management (release)
Cancer-drug developer AmpliMed draws $5M (PE Hub)
Caprotec Bioanalytics receives €6M for protein-analysis tech (release)
ProtAffin draws additional €1.4M for anti-inflammatory drugs (release)
Toxicology-services firm Bridge Labs takes in $18M (release)
Dental-compound maker… Continue Reading

Alder Bio and its yeast-produced antibodies take in $40M

Alder Bio and its yeast-produced antibodies take in $40M

Alder Biopharmaceuticals, a Bothell, Wash., developer of antibody drugs, raised $40 million in a third funding round. Investors included Delphi Ventures, TPG Biotech, Sevin Rosen Funds, Ventures West, H.I.G. Ventures, and WRF Capital.

Alder develops antibody-based drugs for inflammation and autoimmune disease. The company’s lead candidate,… Continue Reading

Life sciences briefing: Thursday, Jan. 3, 2008

Life sciences briefing: Thursday, Jan. 3, 2008

TODAY’S HEADLINES:

Gelesis draws in $16M for obesity treatments (release)
Tempo Pharma raises $8B for nanoparticle drugs (release)
Calistoga Pharma receives additional $5M for cancer and inflammation drugs (release)
Montreux Equity Partners closes $250M life-sciences fund (release)
MTS Health Partners names Andrew Weisenfeld, Mark Epstein managing directors (release)
T2 Biosystems names… Continue Reading

Precision Thera drops IPO, goes public via reverse merger

Precision Thera drops IPO, goes public via reverse merger

(UPDATE: The merger is dead.)

Pittsburgh’s Precision Therapeutics, a biotech working on diagnostics designed to identify the best chemotherapy for cancer patients, appears to have dropped its planned IPO and instead went public via a reverse merger with Oracle Healthcare Acquisition — a “blank check” acquisition firm… Continue Reading

Cancer-drug biotech Agensys sells to Astellas for $387M — but is it a pig in a poke?

Cancer-drug biotech Agensys sells to Astellas for $387M — but is it a pig in a poke?

Yet another biotech has succumbed to Big Pharma’s deep-pocketed blandishments. Agensys, a decade-old Santa Monica, Calif., biotech with an early-stage pipeline, just agreed to sell itself to Japan’s Astellas Pharma for $387 million in cash. The company’s shareholders can receive up to another $150 million… Continue Reading

Life sciences briefing: Monday, Nov. 12, 2007

Life sciences briefing: Monday, Nov. 12, 2007

(UPDATED: See below.)

Featured companies: Anaptys Biosciences, Arterial Remodeling Technologies, Cambria Biosciences, CaseNet, ChemoCentryx, Ensemble Discovery, MediQuest, Piedmont Pharmaceuticals, Raven Biotechnologies, Sensys Medical, Verus Pharmaceuticals, Xanodyne Pharmaceuticals

UPDATED: Expanded items on Anaptys, Arterial Remodeling, Raven Biotech, Sensys and MediQuest. Moved ChemoCentryx and Xanodyne to a separate item.

Antibody-drug maker Raven Biotech… Continue Reading

Life sciences briefing: Friday, Nov. 9, 2007

Life sciences briefing: Friday, Nov. 9, 2007

Featured companies: Antisense Pharma, Arteriocyte, Excelimmune, Fluxion Biosciences

UPDATED: Expanded items on Antisense Pharma, Arteriocyte, and Excelimmune.

Antisense Pharma raises €27M for cancer drugs — Munich’s Antisense Pharma, a biotech developing gene-silencing drugs against cancer, raised €27 million ($38 million) in a fourth funding round. The company’s PDF release… Continue Reading

Life sciences briefing: Wednesday, Oct. 31, 2007

Life sciences briefing: Wednesday, Oct. 31, 2007

Featured companies: AerovectRx, Dicerna Pharmaceuticals, Harmony Information Systems, Intelligent Hospital Systems, Merrion Pharmaceuticals, Syntaxin, SymBio Pharmaceuticals

UPDATED: Expanded items on Harmony Info, SymBio Pharma and Merrion Pharma, added Dicerna item.
UPDATE REDUX: Added Syntaxin item.

U.K. biotech Syntaxin raises £16M for pain and nervous-system drugs — Syntaxin, a U.K. biotech focused… Continue Reading

Life sciences briefing: Monday, Oct. 22, 2007

Life sciences briefing: Monday, Oct. 22, 2007

Featured companies: Ablynx, Avant Immunotherapeutics, BioForm Medical, Celldex Therapeutics, Genomas, High-Throughput Genomics, Orchid Cellmark, ReliaGene Technologies, SarCode, TransMolecular, VisEn Medical

UPDATED: Expanded items on SarCode, Celldex/Avant and Ablynx.
UPDATE REDUX: Added items on BioForm Medical, High-Throughput Genomics and Orchid Cellmark/ReliaGene.

San Francisco’s SarCode draws down $7M for inflammation drugs — The… Continue Reading

Life sciences briefing: Tuesday, Oct. 9, 2007

Life sciences briefing: Tuesday, Oct. 9, 2007

Featured companies: AngioScore, Forsight Labs, Genoptix, Metastatix, Optherion, QLT

UPDATED: See below.

Artery opener AngioScore pulls in $30M — AngioScore, a Fremont, Calif., maker of balloon catheters used to open up clogged arteries, raised $30 million in a fifth funding round. Investors included Telegraph Hill Partners, Psilos Group Management,… Continue Reading